In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles

Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center

(2020) Andrew M Borman et al.   MEDICAL MYCOLOGY

Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole

(2020) Valeria Bernardo et al.   PEDIATRIC TRANSPLANTATION

EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mould and yeast isolates

(2019) Karin Meinike Jørgensen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients

(2019) Lauren Fontana et al.   CLINICAL INFECTIOUS DISEASES

A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles

(2019) Lysett Wagner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

(2019) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values

(2018) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole

(2018) Caitlin R Rausch et al.   CLINICAL INFECTIOUS DISEASES

Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?

(2018) Monica Fung et al.   CLINICAL INFECTIOUS DISEASES

OUP accepted manuscript

(2018)   MEDICAL MYCOLOGY

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories

(2018) Michael A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management

(2018) Pieter P.A. Lestrade et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

(2017) Oliver A Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rapid Identification of Clinically Relevant Members of the Genus Exophiala by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and Description of Two Novel Species, Exophiala campbellii and Exophiala lavatrina

(2017) Andrew M. Borman et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

(2016) Amit Desai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

(2016) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species

(2015) Anuradha Chowdhary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension

(2015) Urshila Durani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales

(2015) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Isavuconazole and Comparators against Clinical Isolates of theMucoralesOrder

(2015) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

(2015) Oliver A. Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Susceptibility Profiles of Amphotericin B and Posaconazole against Clinically Relevant Mucorales Species under Hypoxic Conditions

(2014) Elisabeth Maurer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

(2014) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

In VitroAntifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries

(2014) P.E. Verweij et al.   JOURNAL OF CHEMOTHERAPY

Epidemiology and Clinical Manifestations of Mucormycosis

(2012) George Petrikkos et al.   CLINICAL INFECTIOUS DISEASES

A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)

(2012) F. Lanternier et al.   CLINICAL INFECTIOUS DISEASES

Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)

(2012) A. Skiada et al.   HAEMATOLOGICA

Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study

(2012) J. Auberger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Population Pharmacokinetics of Voriconazole in Adults

(2011) William W. Hope   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

(2011) A. Skiada et al.   CLINICAL MICROBIOLOGY AND INFECTION

Saksenaea erythrospora Infection following Combat Trauma

(2011) D. R. Hospenthal et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Antifungal Susceptibility Profile of Human-Pathogenic Species of Lichtheimia

(2010) A. Alastruey-Izquierdo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Conazoles

(2010) Jan Heeres et al.   MOLECULES

Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole

(2010) George R. Thompson et al.   MYCOPATHOLOGIA

In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

(2009) S. Perkhofer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of antifungals against Zygomycetes

(2009) A. Alastruey-Izquierdo et al.   CLINICAL MICROBIOLOGY AND INFECTION

In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species

(2008) J. Guinea et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation

(2008) F Schlemmer et al.   BONE MARROW TRANSPLANTATION

EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds

(2008)   CLINICAL MICROBIOLOGY AND INFECTION

Fungicidal versus Fungistatic: what's in a word?

(2008) James S Lewis et al.   EXPERT OPINION ON PHARMACOTHERAPY